Evidence map›Paper›PMID 35571739›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

Luteolin Induced Hippocampal Neuronal Pyroptosis Inhibition by Regulation of miR-124-3p/TNF-

Qing Zhu, Pan Meng, Yuanshan Han, Hui Yang, Qin Yang, Zhuo Liu, Yuhong Wang, Minghui Long

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Qing ZhuScience and Technology Innovation Center, Hunan University of Chinese Medicine, Changsha, Hunan Province 410208, China.
Pan MengScience and Technology Innovation Center, Hunan University of Chinese Medicine, Changsha, Hunan Province 410208, China.
Yuanshan HanScience and Technology Innovation Center, Hunan University of Chinese Medicine, Changsha, Hunan Province 410208, China.
Hui YangThe First Affiliated Hospital, Hunan University of Chinese Medicine, Changsha, Hunan 410007, China.ORCID https://orcid.org/0000-0002-6774-2522
Qin YangScience and Technology Innovation Center, Hunan University of Chinese Medicine, Changsha, Hunan Province 410208, China.
Zhuo LiuScience and Technology Innovation Center, Hunan University of Chinese Medicine, Changsha, Hunan Province 410208, China.
Yuhong WangScience and Technology Innovation Center, Hunan University of Chinese Medicine, Changsha, Hunan Province 410208, China.ORCID https://orcid.org/0000-0002-1411-2201
Minghui LongHunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.ORCID https://orcid.org/0000-0002-1025-6216
Hunan University of Traditional Chinese Medicine · CNCentral South University · CNFirst Affiliated Hospital of Hunan University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Breast-cancer-related depression (BCRD) is associated with an increased mortality rate among breast cancer (BC) survivors. Luteolin has many pharmacological effects, particularly in the treatment of BC. In this study, we aimed to explore the anti-BCRD activity of luteolin and its underlying functional mechanism. Methods: A BCRD mouse model was induced by injecting 4T1 cells and corticosterone (COR). Behavioral test, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, Nissl staining, immunofluorescence, reverse-transcription quantitative PCR (RT-qPCR), and western blotting were used to study the effect of luteolin in mice with BCRD in vivo. A COR-induced neuron injury model was established in HT-22 cells in vitro. The role of miR-124-3p in the anti-BCRD effects of luteolin was studied using a miR-124-3p inhibitor. Results: Luteolin significantly reduced the size and weight of the tumor, increased the mice entry frequency in the symmetrical sector, and reduced the duration of immobility in the tail suspension and forced swimming tests of mice affected by BCRD. Simultaneously, apoptosis of hippocampal neurons was inhibited, and the number of Nissl bodies increased with luteolin treatment. In addition, luteolin resulted in the upregulation of miR-124-3p expression in the hippocampus and downregulated the expression of tumor necrosis factor- Conclusion: Our study demonstrated that the anti-BCRD function of luteolin was mediated by regulating the miR-124-3p/TNF-

Identifiers

PMID35571739
PMCPMC9106465
OpenAlexW4229070260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.